FLUXIMINE INJECTION

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

Buy It Now

Active ingredient:
FLUNIXIN AS FLUNIXIN MEGLUMINE
Available from:
Elanco Australasia Pty Ltd
INN (International Name):
flunixin as meglumine(50mg/mL)
Pharmaceutical form:
PARENTERAL LIQUID/SOLUTION/SUSPENSION
Composition:
FLUNIXIN AS FLUNIXIN MEGLUMINE BENZENE Active 50.0 mg/ml
Units in package:
100mL; 50mL
Class:
VM - Veterinary Medicine
Manufactured by:
BAYER AUSTRALIA
Therapeutic group:
CATTLE | DOG | HORSE | PIGS | BEEF | BITCH | BOAR | BOS INDICUS | BOS TAURUS | BOVINE | BUFFALO | BULL | BULLOCK | CALF | CASTRA
Therapeutic area:
MUSCULOSKELETAL SYSTEM
Therapeutic indications:
ANALGESIC | ANTI-INFLAMMATORY AGENT | ANTIPYRETIC | BONE SORENESS | BRUISING | BURSITIS | COLIC | INFLAMMATORY RHEUMATIC ARTHRIT | JOINT DISEASE | LIGAMENT SPRAINS | MUSCLE RELAXANT | MUSCLE SORENESS | OSTEOARTHRITIS | PLATELET ACTIVITY | RHEUMATISM | SEDATIVE | SPASMOLYTIC | SPRAINS | STRAINS | TENDON SPRAINS | TRAUMATIC SWELLING
Product summary:
Poison schedule: 4; Withholding period: WHP: MEAT: Do not use less than 7 days before slaughter for human consumption. WHP: MILK: Milk collected from cows w ithin 36 hours (3 milkings) following t reatment must not be used for human con sumption or processing. This milk shoul d not be fed to bobby calves. WHP: MEAT : (Horses) 28 days.; Host/pest details: CATTLE: [ANALGESIC, ANTI-INFLAMMATORY AGENT]; DOG: [ANALGESIC, ANTI-INFLAMMATORY AGENT]; HORSE: [ANALGESIC, ANTI-INFLAMMATORY AGENT]; PIGS: [ANALGESIC, ANTI-INFLAMMATORY AGENT]; Poison schedule: 4; Withholding period: ; Host/pest details: CATTLE: [ANALGESIC, ANTI-INFLAMMATORY AGENT]; DOG: [ANALGESIC, ANTI-INFLAMMATORY AGENT]; HORSE: [ANALGESIC, ANTI-INFLAMMATORY AGENT]; PIGS: [ANALGESIC, ANTI-INFLAMMATORY AGENT]; Non steroidal anti-inflammatory, analgesic and antipyretic for use in horses, cattle, pigs and dogs.Do not use in cats. Do not use concomitantly with other anti-inflammatory drugs, or with nephrotoxic substances. Use with caution in animals with pre-existing gastrointestinal ulceration, renal, hepatic or haematologic disorders. See also ADVERSE EFFECTS
Authorization status:
Registered
Authorization number:
51812
Authorization date:
2020-07-01

Label image proudly supplied by

infopest@dpi.qld.gov.au

------------------------------,

Samac Laboratories Limited -

Draft

label-

Version Controlled

Ffuximine

tniection :

Printed on

5/01/00

6:02 PM

Page 2

NRA Approval No.

51812/

070",>

Registered to

Bomac Laboratories

Distributed by:

Pharmtech

Limited ABN 77 084 248 206

8 Apollo Ave, West Pymble NSW 2073

Orders

&

Product

Information

0500886668

www.pharmtech.com.au

Product

Leaflet

PRESCRIPTION

ANIMAL

REMEDY

KEEP OUT OF THE REACH OF CHILDREN

ANIMAL

TREATMENT ONLY

FLUXIMINE INJECTION

ACTIVE CONSTITUENT

FLUNIXIN

meglumine)

mgfmL

Non-steroidal

antl-lntlammatcry,

analgesic and

antipyretic

in horses,

cattle,

pigs and

dogs.

PHARMACOLOGY

Actions

Flunixin meglumine is a non-steroidal

anti-inflammatory agent with analgesic and antipyretic activity.

Flunixin,

through inhibition of

cyclooxyqenase.

blocks synthesis of

eicoeanoids,

including prostaglandins,

thromboxane,

and prostacyclln (PGI

which are chemical

mediators of

inflammation,

the NSAIDs,

flunixin is considered to be the

most

potent

cyclooxygenase inhibitor.

In contrast

to other

NSAIDs,

therapeutic pharmacological

effects are associated

with relatively low plasma levels of

flunixin.

is reported to be a more potent

analgesic than meclofenamic acid,

phenylbutazone,

naproxen.

salicylic acid,

pentazocine lactate,

pethidine hydrochloride,

and codeine phosphate,

and to

provide cornparabte analgesia to

clinically

effective

doses

morphine.

Analgesic and antiinflammatory effects of

flljnixin .

are dose-related and tolerance,

as occurs with narcotic agents,

apparently does not develop to the action

flunbdn.

Clinical

studies have confirmed the analgesic and antiinflammatory efficacy of

flunixin in the therapy of

musculoskeletal

disorders in horses and dogs,

and of

colic in horses.

In equine colic models flunixin analgesia has been found superior to

that

pethidine.

Flunixin does not

significantly alter gastrointestinal

motility,

blood pressure,

or cardiac rhythm in horses,

Thromboxane and prostacyclin are involved in the adverse haemodynamic changes associated with endotoxic shock.

Flunixin

administration

decreases

endotoxin-induced

lactic

acidosis,

reduces

severity

arterial

hypotension

endothelial

cell

injury,

and improves venous return.

Fiunixin treatment

dogs with experimental

coli

septicaemia

prevents arterial

hypotension and hypoxaemia and has resulted in improved animal

survival.

Vascular changes in uveitis may be mediated at

least

in part

by endogenous prostaglandin release,

and a cause and effect

relationship

between

prostaglandin

release

subsequent

increase

aqueous

protein

concentration

been

established.

Administration of

flunixin prior

to intraocular

surgery is effective in reducing aqueous humour prcetacyclin

Bomac Laboratories Limited -

Draft Label -

Version Controlled

Fluximine Injection

Printed on

5/01/00

6:02 PM

Page 3

accumulation in the horse.

Intravenous flunixin,

alone or in combination with a corticosteroid,

has been shown to reduce

aqueous flare in dogs after intraocular surgery,

Pharmacokinetics

Flunixin has a rapid onset

and long duration of action.

Therapeutic effects are manifest within 2 hours after parenteral

oral

administration.

Peak response is reached between 12 and 16 hours after administration,

and duration of

action is up

to 36 hours.

The plasma half-life is reported to be 1.6 hours in horses, 3.7 hours in dogs,

and 8.1 hours in cattle.

Flunixin is widely distributed throughout body tissues and fluids.

Renal

excretion

is significant

in the elimination of

ffunbdn,

which is excreted in the urine largely in conjugated form.

Excretion via bile and other gastrointestinal

secretions may also

occur.

Flunixin is detectable,

by conventional

analytical

methods,

in equine urine for at least 72 hours after dosing and may

be detectable by some techniques for up to 15 days after administration.

Drug clearance

time after sequential

doses does

not differ significantly from that

following a single dose.

Flunixin apparently does not

accumulate in body tissues.

N$AIDs however, being acidic,

have a propensity to accumulate

sites

low pH such

regions

inflammation.

In experimental

models

acute inflammation

in horses,

concentrations of

f1unixin

in inflammatory exudate have been found to be higher

than those in plasma by 6 hours after

intravenous administration of

a single therapeutic dose.

Flunixin suppresses the production of

in inflammatory

exudates for 12 to 24 hours after a single intravenous dose.

The long pharmacological

action of flunixin is at variance with

its short

plasma half-life

in the horse.

This may be attributable to the capacity

NSAIDs to irreversibly bind to

cycJooxygenase,

the accumulation of

flunixin at

inflammatory sites,

and the prolonged excretion of

the agent

from the

body.

CLINICAL APPLICATION

Fluximine Injection

provides effective antiinflammatory and analgesic action in a wide range of

musculoskeletal

disorders

in horses,

dogs, cattle and pigs.

In those species it may be used in the therapy of arthritis,

myositis,

and traumatic injuries

resulting in fractures and contusions.

Fluximine Injection

administration results in effective visceral

analgesia in cases of

equine colic due to flatulence or

inflammatory causes.

Flunixin is considered to be a more potent

analgesic than many of

the narcotic or

other

non-

steroidal

antiinflammatory drugs and is widely used in the therapy of

equine colic.

Flunixin,

when used in the therapy of

equine

colic,

mask

behavioural

cardiopulmonary

signs

associated

with

enootoxaemia

intestinal

devitalisation.

- Intravenous administration of

flunixin has been advocated in the therapy of

ocular

inflammatory conditions,

and may be

employed pre-

and post-operatively to reduce inflammation resulting from intraocular

surgery in the horse and dog.

Fluximine Injection

may be a useful

alternative,

or adjunct,

to corticosteroids in such cases.

Flunixin may be administered

subconjunctivally prior to intraocular surgery in the horse to reduce aqueous humour prostacyclin accumulation.

Flunixin has been used successfully to reduce the adverse haemodynamic changes,

which characterise endotoxic shock

in both horses and dogs, The agent is also recommended as an adjunct to the therapy of Mastitis-Metritis-Agalactia (MMA)

syndrome in sows. Therapeutic effects in such cases are observed at, or below, antiinflammatory does rates of flunixin.

In cattle,

Ffuximine Injection

is used for

its antiinflammatory and analpcclc actions in the therapy of

aseptic lamln'tis and

peripheral

nerve injury resulting from direct trauma or pressure.

Flunixin administered intravenously at

mg/kg

daily has

also been recommended as an adjunct

to the treatment of persistent hyperthermia.

Fluximine Injection

may be administered either

intravenously or intramuscularly with comparable efficacy,

and onset

duration of action.

Flunixin has a long pharmacological

action,

and therapeutic effects are maintained even at

low plasma

concentrations.

Care should be taken to avoid intra-arterial

injection of

flunixin as it may cause transient

CNS stimulation,

ataxia, hyperventilation,

and muscle weakness.

Flunixin has a wide margin of safety and reports of adverse reactions are rare at therapeutic dose rates and recommended

treatment

durations.

Intravenous administration of

flunixin at

up to five times the recommended dose rate and for

twice

the recommended treatment

period have been reported to produce no gross clinical

abnormalities and no changes in

haematological,

biochemical

or urinary parameters.

Parenteral

administration of the agent

rarely causes tissue irritation;

Bomac Laboratories Limited -

Draft Label -

Version Controlled

Flux/mine Injection

- Printed on 5/01/00 6:02 PM

Page 4 of 6

may be slightly irritant

when administered by intramuscular injection to young animals or

injected too superficially into

older animals.

Safety of the use of flunixin during pregnancy has not been established.

DIRECTIONS FOR USE

use in cats.

admix

syringe

with

other

compounds.

concomitantly

with

other

antiinflammatory drugs,

with

nephrotoxic substances.

with

caution

In animals

with

preexisting gastrointestinal

ulceration, renal,

hepatic

haematologic

disorders.

USE ALL PRODUCT WITHIN 28 DAYS OF OPENING

ADVERSE EFFECTS

Occasional

cases

localised swelling,

induration,

muscle

stiffness,

and sweating have been reported

following

intramuscular injection of flunixin in horses.

A case of

flunixin toxicity has been reported in a pony mare after intravenous administration of

flunixin at

greater than 5

times

the recommended

dose for

5 days.

Clinical

signs observed included anorexia,

depression,

gastrointestinal

ulceration, hypoproteinaemia and neutropaenia.

In dogs treated with

f1unixin

at excessive doses or for prolonged periods;

vomiting, diarrhoea, and gastrointestinal

ulceration may occur.

Horses:

mg/kg

mL/45kg) bodyweight daily for up to 5 days, by intravenous or intramuscular injection.

Cattle:

1.1 - 2.2 mg/kg (1-2

mU45

kg) bodyweight daily for 3 to 5 days, by intravenous Or intramuscular injection.

Pigs:

1.1 - 2.2

mg/kg

mll45

kg) bodyweight

daily

for up to 3 days,

deep intramuscular injection.

Dogs:

1 mg/kg (0.2

mll10

kg) bodyweight daily for up to 3 days, by intravenous or intramuscular injection.

with other NSAIDs, flunixin should be used cautiously in conjunction with highly protein-bound drugs such as phenytoin,

valproic acid, oral anticoagulants, other antiinflammatory agents, and sulfonamides.

Prostaglandins have a cytoprotective action on the gastric mucosa,

and in some species maintenance of

renal

blood flow

in hypovolaemic states is prostaglandin dependent.

Flunixin should therefore be used with caution in conjunction with

ulcerogenic

nephrotoxic

agents,

in cases

pre-existing

gastrointestinal

ulceration or

renal

disease,

hypovalaemic patients.

Care should be exercised in the use of

flunixin in patients with hepatic disease,

haematological

disorders or severe cardiac failure.

WITHHOLDING PERIODS:

MEAT:

DO NOT USE LESS than 7 days before

slaughter

human consumption.

MILK:

Milk

collected

from

cows

within

hours

milkings)

following

treatment

MUST NOT BE USED

human

consumption

processing.

This

milk

should

be fed to

bobby

calves.

MEAT WITHHOLDING PERIOD (HORSES) 28 DAYS.

DISPOSAL

Dispose of empty container by wrapping with paper and putting in garbage.

1-·=-=:::=======----------------

Samac

Laboratories

limited -

Draft

Label-

Version

Controlled

Fluximine Injection

-

Printed

on

5/01/00

6:02 PM

Page 5 of 6

STORAGE

Store

below

30°

(Room Temperature).

51812/

0:1-03

Registered

to:

Distributed

by:

BOMAC LABORATORIES LIMITED NEW ZEALAND

Pharmtech

Limited

ACN 084 248 206

Apollo

Avenue,

West

Pymble NSW 2073

Orders

&

Product Information 0500 886 668

www.pharmtech.com.au

Carton Label

Front

Cover

&

Back Cover

PRESCRIPTION

ANIMAL

REMEDY

KEEP

REACH

CHILDREN

ANIMAL

INJECTION

ONLY

FLUXIMINE INJECTION

ACTIVE

CONSTITUENT:

Flunixin (as meglumine) SOmg/mL

Non Steroidal

anti-inflamamatory,

analgesic and antipyretic for use in horses,

cattle,

pigs and dogs.

SOmL [IOOmL]

Manufactured

by Samac

Laboratories

limited (NZ) and

distributed

by

Pharm

Tech Ply

Limited,

8

Apollo

Ave, West

Pymble

NSW2073.

Orders

&

Product Information

0500886668

Carton Label

Side Covers

READ THE ENCLOSED LEAFLET BEFORE USING THIS PRODUCT.

DIRECTiONS FOR USE:

Do not use in cats.

USE ALL PRODUCT WITHIN 28

DAYS

OF OPENING

Horses

1.1 mg/kg bodyweigbt

(lmL

per 45kg) daily for up to

5 days,

by IV or 1M injection.

Cattle

Dogs

Swine

WITHHOLDING PERIODS:

Bomac Laboratories

limited

Draft

label-

Version Controlled

Fluximine

Injection

Printed on

5/01/00

6:02 PM

Page 6 of

2.2 rug/kg bodyweight (1-2mL

45kg) daily

up to

days

1M injection.

mg/kg

bodyweight (O.2mL

lOkg) daily for

days,

1M injection.

1.1 to 2.2 mg/kg bodyweigbt (1-2mL

45kg) daily

up to

days, by deep 1M injection.

MEAT: DO NOT USE LESS than 7

days

before

slaughter

human

consumption.

MILK:

Milk

collected

from

cows

within

hours

milkings)

following

treatment

MUST NOT BE USED

human

consumption

processing.

This

milk

should

be fed to

bobby

calves.

MEAT WITHHOLDING PERIOD (HORSES) 28 DAYS.

Dispose

empty container by wrapping with paper and placing in garbage.

Store below 30°C (Room Temperature).

© 1999

NRA Approval

51812/O'hY)

Registered to

Bomac

Laboratories

Distributed by:

Pharmtecb

Limited ACN 084 248 206

8 Apollo Ave,

West

Pymble NSW 2073

Orders

&

Product

Information

0500886 668

www.pharmtech.com.au

Page1of 6

SAFETY DATA SHEET A18290/03/AUS

FLUXIMINEINJECTION

SECTION 1–IDENTIFICATION,CONTACTS

BayerAustraliaLtd

875 PacificHighway

PymbleNSW2073 EmergencyTelephoneNumber

1800 033 111

24 hourEmergencyServiceAustraliaWide,Toll Free

ContactPoint(fornon-emergencycalls)

Animal HealthDivision

(02)93916000

FullProductName FLUXIMINEINJECTION

OtherNames N/A

ProductUse FORANIMALTREATMENTONLY

Forthetreatment ofinflammatoryandpainful conditionsin horses,

cattle anddogs.

CreationDate 9 th May2011

Revision Date 3 September2013

SECTION 2–HAZARDSIDENTIFICATION

HazardClassification CLASSIFIED ASANONHAZARDOUSSUBSTANCE

CLASSIFIED ASA NON DANGEROUSGOOD

accordingtocriteriaofNOHSCAustraliaand ADGCode.

PoisonSchedule4

RiskPhrases None allocated.

SafetyPhrases None allocated

SECTION 3–COMPOSITION

Ingredients CASNo Proportion

FlunixinMeglumine 42461-84-7 5% w/v

Thisisa commercialproductwhose exactratioofcomponentsmayvaryslightly.Othernon-

hazardousingredientsarealso present.

A18290/03/AUSFLUXIMINEINJECTION Page2of 6

SECTION 4–FIRSTAID MEASURES

First AidStatement Ifpoisoningoccurs,contactadoctororPoisonsInformation Centre.

PhoneAustralia131126.

Scheduled Poisons Poison Schedule4

PoisonsInformation Centresin each Statecapitalcitycan provide

additionalassistanceforscheduled poisons. Phone131126.

Inhalation Removefromfurtherexposure.Ifunconsciousnessoccurs, seek

immediatemedical attention.Ifbreathinghasstopped, usemouth to

mouth resuscitation.

Skin contact Removecontaminatedclothingand clean beforereuse. Wash all

exposed areasofskin with plentyofsoap and water. Seek medical

attentionifirritationdevelops.

Eye contact Hold eyelidsopenand flush with asteady,gentlestreamofwaterfor

atleast15 minutesoruntil chemical isremoved.Seekmedicaladvice

ifirritationpersists.

Ingestion Ifpoisoningoccurs,contactadoctororPoisonsInformation Centre,

phone13 1126.Ifswallowed, and ifmorethan 15minutesfroma

hospital, inducevomiting, preferablyusingIpecacSyrup APF.

Adviceto doctor Treat symptomatically.

SECTION 5–FIREFIGHTINGMEASURES

Flammability Non-flammable.

ExtinguishingMedia Use foam,drychemicalpowder, carbon dioxideorwatersprayfire

extinguishers. Usewaterspraysto coolfireexposed surfacesand any

adjacentstorage vessels.

FireandExplosion

Hazards None applicable.

Hazardous

Combustion Products Not combustible.Onlysmall quantitiesofdecomposition products

areexpectedfromthisproductattemperaturesnormallyachievedina

fire. Thiswillonlyoccurafterheatingto dryness.Firedecomposition

productsfromthisproductarelikelyto betoxicand corrosiveif

inhaled. Takeappropriateprotective measures.

FireFighting Wearself-contained breathingapparatusand fullprotectiveclothing

inaccordancewithnormalfire-fightingprocedures.

A18290/03/AUSFLUXIMINEINJECTION Page3of 6

SECTION 6–ACCIDENTALRELEASEMEASURES

AccidentalRelease EmergencyProcedures:Noneapplicable.

Method ofContainmentand Clean up Procedures

Absorb spillswith absorbentpaper,cloth orotherabsorbentmaterial

(e.g. sand, soil)and disposeofin garbage.Contaminatedmaterial

should beremoved and placed in asuitablelabeled containerfor

wastedisposal. Treatspillareawith plentyofwater. Do notallow

productto reach sewagesystem, surfaceorground water. Restrict

personsnotwearingprotectiveequipmentfromenteringareauntil

clean up iscomplete. Useappropriatepersonalprotectiveequipment

duringclean up.

SECTION 7–HANDLINGAND STORAGE

Safe Handling Avoid allpersonalcontact. Do notsmoke, eatordrink whilehandling

orusingtheproduct. Observegood personalhygienebywashing

handsbeforeandafteruse. Removeclothingifitbecomes

contaminatedandwashseparately.Vialsshould alwaysbekept

closed in storageand stored in originallabeled pack.Alwayshandle

productaccordingto labelto ensureproductintegrity.

Storage Storebelow30 °C (Roomtemperature).Storeonlyin original

containers.Keep awayfromchildren.

SECTION 8–EXPOSURECONTROLSAND PERSONALPROTECTION

ExposureLimits Therearenoexposurelimitsestablished forthisformulation.Use

onlyasdirected.

TheADIforFlunixin meglumineissetat0.006mg/kg/day. The

correspondingNOELissetat0.6mg/kg/day.

ValuestakenfromAustralianADIList,Dec2004.

Ventilation Naturalventilation should beadequateundernormaloperating

conditions.Iftheairconcentration ofvapourormist ishigh,the

processshould bemodified to reducetheproblem.

Eye Protection Eye protectionsuchasprotectiveglassesorgogglesisrecommended

when thisproductisbeingused.

Skin Protection Wearchemicalprotective gloveswhenskincontactislikely.Wash

handsorotherexposed areasafterhandlingand use.

Respirator No specialrespiratoryprotection equipmentisrecommended under

anticipated conditionsofnormaluse.

Thermalhazards Non flammableproduct. No specialprotectiveequipment isrequired.

A18290/03/AUSFLUXIMINEINJECTION Page4of 6

SECTION 9–PHYSICAL&CHEMICALPROPERTIES

Physical State Liquid

Appearance Aclearalmost colourlessliquid

Odour Characteristicodourofphenol

Boilingpoint Approximately100°Cat100kPa

Freezingpoint Approximately0°C

Solubilityinwater Completelysoluble.

SECTION 10–STABILITY&REACTIVITY

Chemical Stability Stableundernormalambientand anticipated storageconditionsof

temperature and pressure

Conditionsto Avoid Noneknown

Incompatible

Materials Strongacids, strongbases, strongoxidisingagents

Hazardous

Decomposition Firedecomposition productsfromthisproductarelikelyto betoxic

and corrosiveifinhaled.

HazardousReactions Polymerisation willnotoccur.

SECTION 11–TOXICOLOGICALINFORMATION

Reproductive Effects No evidenceofreproductiveeffectshasbeenobtained.

Mutagenicity Noevidence ofmutagenic effectshasbeenobtained.

Carcinogenic Effects No evidenceofcarcinogeniceffectshasbeenobtained.

HealthHazard

Information Thisproductisunlikelyto presentahazard during normaluse.

ACUTE

Selfinoculation

Accidentalself-injectionisthemostlikelyrouteofexposure.

Flunixin

Lo 39.6mg/kgIVin Domesticanimal(sheep,goat)

(gastriculceration/bleeding, altered fluid intake)

Swallowed

Flunixin maybeabsorbed fromoralmucousmembranesand the

gastrointestinal tract.Can beharmfulifswallowed. Maycause

gastrointestinaldisturbances, nausea, headache, vomitingand CNS

depression.

(oral)rat120mg/kg

EyeIrritatingtotheeyesandmucousmembranes.

SkinMayirritateskin.

InhaledHarmful ifinhaled.Maycauseirritationoftherespiratory

tractandmucousmembranes.Maycause nausea,headache,dizziness

vomitingand CNSdepression. Prolonged inhalation mayproduce

pulmonaryedema.

CHRONIC

No information available.

A18290/03/AUSFLUXIMINEINJECTION Page5of 6

SECTION 12–ECOLOGICALINFORMATION

Ecotoxicity No information available.

SECTION 13–DISPOSALINFORMATION

Spillsand disposal

Clean up spilled materialwith absorbentensuringno contactwith

skin duringoperationby usingappropriatepersonalprotective

equipmentduringclean up.Flush contaminated areawith waterand

detergent.Dispose ofwaste inaccordance withlocal,state orfederal

laws.Disposeofemptycontainerbywrappinginpaperandputtingin

garbage.

SECTION 14–TRANSPORTINFORMATION

UN No None allocated

UNProperShipping

Name None allocated

Class&Subsidiary

Risk None allocated

PackagingGroup None allocated

HazchemCode None allocated

SECTION 15–REGULATORY INFORMATION

PoisonsSchedule Schedule4

All significant ingredientsinthisformulationcanbefound in the

publicAustralianInventoryofChemicalSubstances(AICS).

APVMARegistration TheproductisregisteredwiththeAPVMA.

RegistrationNumber 51812

Labelling Allnecessarydirections,precautionsandwarningsfornormaluseof

theproductareincludedon theproductlabel.

A18290/03/AUSFLUXIMINEINJECTION Page6of 6

SECTION 16–OTHERINFORMATION

SummaryofChanges

fromLast Edition Routineupdate.

Acronyms ADGCodeAustralian CodefortheTransportofDangerousGoods

byRoadand Rail

ADIAcceptable DailyIntake

APVMAAustralianPesticidesandVeterinaryMedicinesAuthority

CASChemical AbstractsServiceRegistryNumber

LD

Lo (LethalDoseLow)-theminimum amount ofachemical which

testshaveshown tobe lethaltoa specifiedtype ofanimal

LD

50 Lethaldosefor50%ofanimalstested

NOELNo-observable-effect-level.

NOHSCNational Occupational Health&SafetyCommission

UN NumberUnited Nationsnumber

Disclaimer ThisSafetyData Sheethasbeen developed accordingto theNOHSC

NationalCode ofPractice forthe PreparationofMSDS

[NOHSC:2011(2003)]. Thedata, information andrecommendations

herein ("information")arerepresented ingood faith and believed to

be correctasofthe datehereof. ThepurposeofthisSafetyData Sheet

isto describeproductin termsoftheirsafetyrequirements. Bayer

AustraliaLimitedmakesno representation ofmerchantability, fitness

foraparticularpurposeorapplication, orofanyothernaturewith

respectto theinformation ortheproductto whichtheinformation

refers("theproduct"). Theinformation issupplied upon thecondition

that thepersonsreceivingsamewill maketheirowndeterminationas

to itssuitabilityfortheirpurposespriorto useoftheproduct. The

physicaldata shownhereinare typicalvaluesbasedonmaterial

tested. Thesevaluesshould notbeconstrued asaguaranteed analysis

ofanyspecificlotorasguaranteed specification fortheproductor

specific lotsthereof.Duecareshould betaken tomakesurethatthe

useordisposalofthisproductand /oritspackagingisin compliance

with relevantFederal, StateandLocalGovernmentregulations.

END OFSDS

Document Outline

Similar products

Search alerts related to this product

View documents history

Share this information